Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial

Angulo, Paul; Dickson, E. Rolland; Therneau, Terry M.; Jorgensen, Roberta A.; Smith, Coleman I.; DeSotel, Carolee K.; Lange, Stephen M.; Anderson, Marlys; Mahoney, Douglas W.; Lindor, Keith D.

doi:10.1016/s0168-8278(99)80136-6

Cited by 116 publications

(80 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, Angulo et al published a study of a comparison of 3 doses of UDCA in the treatment of primary biliary cirrhosis. 30 They observed that 5 to 7 mg/kg/d was a suboptimal dose, whereas there was no difference between 13 to 15 mg and 23 to 25 mg/kg/d. The dose of 13 to 15 mg/kg/d was recommended.…”

Section: Discussionmentioning

confidence: 99%

Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation

Ruutu

Eriksson

Remes

et al. 2002

Blood

236

168

View full text Add to dashboard Cite

The role of ursodeoxycholic acid (UDCA) in the prevention of hepatic complications after allogeneic stem cell transplantation was studied in a prospective randomized open-label multicenter trial. A total of 242 patients were allocated to receive (n ‫؍‬ 123) or not to receive (n ‫؍‬ 119) UDCA in the dose of 12 mg/kg/d orally from the day preceding the conditioning until day 90 after transplantation. In the UDCA-treated group a significantly smaller proportion of patients developed a serum bilirubin level exceeding 50 M (18 of 123 versus 31 of 119, P ‫؍‬ .04), and similarly a smaller proportion of patients exceeded the alanine aminotransferase level of 100 U/L. There was no difference in the incidence of veno-occlusive disease of the liver. Compared to the control group, in the UDCA-treated group there was a nonsignificant trend toward a lower overall incidence of acute graft-versushost disease (GVHD) and a significantly lower incidence of grade III to IV acute GVHD (5 of 123 versus 17 of 119, P ‫؍‬ .01), stage II to IV liver and intestinal GVHD, and stage III to IV skin GVHD. There was no difference in the incidence of chronic GVHD or in the relapse rate. Among the patients given UDCA, the survival at 1 year was significantly better, 71% versus 55% (P ‫؍‬ .02), and the nonrelapse mortality rate was lower, 19% versus 34% (P ‫؍‬ .01), than in the control group. There were significantly more deaths in GVHD in the control group. In conclusion, UDCA administration reduced hepatic problems and severe acute GVHD and improved survival. These results suggest a role for UDCA in the prevention of transplantrelated complications in allogeneic transplantation.

show abstract

Section: Discussionmentioning

confidence: 99%

Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation

Ruutu

Eriksson

Remes

et al. 2002

Blood

236

168

View full text Add to dashboard Cite

show abstract

“…The only significant side effect is diarrhea, which probably occurs in less than 5% of patients. According to biochemical data and the Mayo risk score, no further improvement is achieved when higher doses are administered [25,26]. Less than 10 mg/kg/day seem to be not effective [27].…”

Section: Ursodeoxycholic Acid In Primary Biliary Cirrhosismentioning

confidence: 99%

“…A recent study demonstrated that patients receiving UDCA had a lower incidence of major complications and lower medical care costs compared to patients receiving placebo [24]. Based on these studies, UDCA has been established as the treatment of choice for PBC since it is safe and well tolerated in a dosage of 5-25 mg/kg/d [25]. The recommended dosage in PBC is 13-15 mg/kg/d [25].…”

Section: Ursodeoxycholic Acid In Primary Biliary Cirrhosismentioning

confidence: 99%

See 1 more Smart Citation

Drug therapy of primary biliary diseases: classical and modern strategies

Schlichting

Leuschner

2001

J Cellular Molecular Medi

View full text Add to dashboard Cite

“…Obecnie jest on jedynym lekiem stosowanym w tej chorobie zaaprobowanym przez US Food and Drug Administration w optymalnej dawce 13-15 mg/kg m.c./dobę, przede wszystkim u osób z nieprawidłowymi wynikami badań biochemicznych, niezależnie od nasilenia zmian histopatologicznych w wątrobie [7,8]. Wykazano, że ani mniejsze (5-7 mg/kg m.c./dobę), ani większe (23-25 mg/kg m.c./ dobę) dawki nie spełniają kryterium skuteczności w odniesieniu do poprawy wyników badań biochemicznych i zahamowania wątrobowych zmian histopatologicznych [9], a lepszą odpowiedź uzyskuje się u pacjentów z wczesnymi zmianami histopatologicznymi niż z bardziej zaawansowanymi [10]. Zgodnie z tzw.…”

Section: Pierwotna Marskość żółCiowa Wątrobyunclassified

Ursodeoxycholic acid in liver diseases

Juszczyk¹

2012

View full text Add to dashboard Cite

show abstract

Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial

Cited by 116 publications

References 22 publications

Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation

Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation

Drug therapy of primary biliary diseases: classical and modern strategies

Ursodeoxycholic acid in liver diseases

Contact Info

Product

Resources

About